A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
An Open-Label, Single-Arm, Phase 4 Study to Assess Glycemic Control When Adults With Type 2 Diabetes Switch From a GLP-1 RA to Tirzepatide (SURPASS-SWITCH-2)
Eligibility
Inclusion Criteria
- Have Type 2 diabetes (T2D)
- Have an HbA1c c ≥6.5% (≥48 mmol/mol) to ≤9.0% (≤75 mmol/mol)
- Have a body mass index (BMI) ≥25 kilogram per square meter (kg/m²) at screening
- Have been on a stable treatment dose of 1 of the listed GLP-1 RAs for ≥3 months
- No treatment with oral antidiabetic medicine (OAM) or on stable doses (for at least 3 months before screening) of up to 3 OAM. The OAM may include metformin, sodium-glucose linked transporter-2 inhibitor (SGLT-2i), thiazolidinediones, or α-glucosidase inhibitors.
Exclusion Criteria
- Have Type 1 Diabetes (T1D)
- Have a clinical history of
- proliferative diabetic retinopathy
- diabetic maculopathy, or
- nonproliferative diabetic retinopathy that requires acute treatment
- Are at high risk for cardiovascular disease or have a history of
- myocardial infarction
- percutaneous coronary revascularization procedure
- carotid stenting or surgical revascularization
- nontraumatic amputation
- peripheral vascular procedure
- cerebrovascular accident
- or hospitalization for congestive heart failure
- Have New York Heart Association (NYHA) Functional Classification Class IV congestive heart failure
- Have a history of ketoacidosis or hyperosmolar state or coma
- Have a history of severe hypoglycemia or hypoglycemia unawareness within the 6 months.